Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2006, Advent Life Sciences is a London-based venture capital firm specializing in life sciences. The firm has brought 15 innovative medicines and products to approval and primarily invests in early and mid-stage companies across the UK, Europe, and the USA. Advent Life Sciences manages a diverse portfolio and focuses on building businesses that transform scientific breakthroughs into market-ready solutions.
Advent Life Sciences invests in new drug discovery, medical technology, enabling technologies, and vaccines. The firm typically engages with companies at the Seed stage or Series A, employing a first-in-class or best-in-class investment approach. Check sizes are not specified, but the focus is on innovative life sciences businesses.
Notable portfolio companies include Agenus, which has developed a broad immunotherapy platform for cancer; Beacon Therapeutics, known for pioneering ocular gene therapy; Algeta, focused on alpha-emitter anticancer agents; Axonics, which offers a novel sacral neuromodulation system; Levicept, developing a pain treatment for osteoarthritis; and UniQure, specializing in gene therapy for rare diseases.
To pitch Advent Life Sciences, email your deck to contact@adventls.com.
As of October 2023: Advent Life Sciences has highlighted significant developments from its portfolio, including Levicept's FDA acceptance of an IND application for an osteoarthritis treatment and Beacon Therapeutics' successful closing of an oversubscribed Series C financing round exceeding $75 million.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.